Gut bacteria pill tested to boost cancer drug power
NCT ID NCT03595683
Summary
This study tested whether taking an oral pill containing specific gut bacteria (EDP1503) could improve the effectiveness of a standard immunotherapy drug (pembrolizumab) for people with advanced melanoma. It involved two groups: patients new to this type of immunotherapy and those whose cancer had stopped responding to it. The trial was terminated early after enrolling only 8 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.